Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 48

1.

RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer.

Robert NJ, Diéras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, Perez EA, Yardley DA, Chan SY, Zhou X, Phan SC, O'Shaughnessy J.

J Clin Oncol. 2011 Apr 1;29(10):1252-60. doi: 10.1200/JCO.2010.28.0982. Epub 2011 Mar 7.

2.

Bevacizumab: a review of its use in combination with paclitaxel or capecitabine as first-line therapy for HER2-negative metastatic breast cancer.

Croom KF, Dhillon S.

Drugs. 2011 Nov 12;71(16):2213-29. doi: 10.2165/11207720-000000000-00000. Review.

PMID:
22035518
4.

Bevacizumab in combination with a taxane for the first-line treatment of HER2-negative metastatic breast cancer.

Rodgers M, Soares M, Epstein D, Yang H, Fox D, Eastwood A.

Health Technol Assess. 2011 May;15 Suppl 1:1-12. doi: 10.3310/hta15suppl1/01. Review.

5.

Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials.

Valachis A, Polyzos NP, Patsopoulos NA, Georgoulias V, Mavroudis D, Mauri D.

Breast Cancer Res Treat. 2010 Jul;122(1):1-7. doi: 10.1007/s10549-009-0727-0. Epub 2010 Jan 9. Review.

PMID:
20063120
6.

Interaction between Herceptin and taxanes.

Diéras V, Beuzeboc P, Laurence V, Pierga JY, Pouillart P.

Oncology. 2001;61 Suppl 2:43-9. Review.

PMID:
11694787
7.

Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline.

Giordano SH, Temin S, Kirshner JJ, Chandarlapaty S, Crews JR, Davidson NE, Esteva FJ, Gonzalez-Angulo AM, Krop I, Levinson J, Lin NU, Modi S, Patt DA, Perez EA, Perlmutter J, Ramakrishna N, Winer EP; American Society of Clinical Oncology.

J Clin Oncol. 2014 Jul 1;32(19):2078-99. doi: 10.1200/JCO.2013.54.0948. Epub 2014 May 5. Review.

PMID:
24799465
8.
9.

Role of Herceptin in primary breast cancer: views from North America and Europe.

Leyland-Jones B, Smith I.

Oncology. 2001;61 Suppl 2:83-91. Review.

PMID:
11694792
10.

Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer.

Chan A, Miles DW, Pivot X.

Ann Oncol. 2010 Dec;21(12):2305-15. doi: 10.1093/annonc/mdq122. Epub 2010 Mar 24. Review.

11.

Sorafenib in locally advanced or metastatic breast cancer.

Gradishar WJ.

Expert Opin Investig Drugs. 2012 Aug;21(8):1177-91. doi: 10.1517/13543784.2012.689824. Epub 2012 May 23. Review.

PMID:
22616580
12.

Current combination chemotherapy regimens for metastatic breast cancer.

Schwartz J.

Am J Health Syst Pharm. 2009 Dec 1;66(23 Suppl 6):S3-8. doi: 10.2146/ajhp090438. Review.

PMID:
19923317
13.

The role of angiogenesis inhibition in the treatment of breast cancer.

Sledge GW Jr, Rugo HS, Burstein HJ.

Clin Adv Hematol Oncol. 2006 Oct;4(10 Suppl 21):1-10; quiz 11-2. Review.

PMID:
17139244
14.

Bevacizumab: in first-line treatment of advanced and/or metastatic renal cell carcinoma.

Frampton JE, Keating GM.

BioDrugs. 2008;22(2):113-20. Review.

PMID:
18345708
15.

Bevacizumab for the first-line treatment of human epidermal growth factor receptor 2-negative advanced breast cancer.

Damasceno M.

Curr Opin Oncol. 2011 Apr;23 Suppl:S3-9. doi: 10.1097/01.cco.0000397417.75245.9c. Review.

PMID:
21490481
16.

The European Medicines Agency Review of Pertuzumab for the treatment of adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer: summary of the scientific assessment of the committee for medicinal products for human use.

Boix-Perales H, Borregaard J, Jensen KB, Ersbøll J, Galluzzo S, Giuliani R, Ciceroni C, Melchiorri D, Salmonson T, Bergh J, Schellens JH, Pignatti F.

Oncologist. 2014 Jul;19(7):766-73. doi: 10.1634/theoncologist.2013-0348. Epub 2014 Jun 13. Review.

17.

nab-Paclitaxel in combination with biologically targeted agents for early and metastatic breast cancer.

Megerdichian C, Olimpiadi Y, Hurvitz SA.

Cancer Treat Rev. 2014 Jun;40(5):614-25. doi: 10.1016/j.ctrv.2014.02.001. Epub 2014 Feb 12. Review.

PMID:
24560997
18.
19.

Efficacy of biological agents in metastatic triple-negative breast cancer.

Bramati A, Girelli S, Torri V, Farina G, Galfrascoli E, Piva S, Moretti A, Dazzani MC, Sburlati P, La Verde NM.

Cancer Treat Rev. 2014 Jun;40(5):605-13. doi: 10.1016/j.ctrv.2014.01.003. Epub 2014 Feb 4. Review.

PMID:
24529896
20.

Meta-analysis of phase III trials of docetaxel alone or in combination with chemotherapy in metastatic breast cancer.

Belfiglio M, Fanizza C, Tinari N, Ficorella C, Iacobelli S, Natoli C; Consorzio Interuniversitario Nazionale per la Bio-Oncologia (CINBO).

J Cancer Res Clin Oncol. 2012 Feb;138(2):221-9. doi: 10.1007/s00432-011-1091-0. Epub 2011 Nov 18. Review.

Items per page

Supplemental Content

Write to the Help Desk